{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:45:53Z","timestamp":1773715553092,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To describe the incidence, management, and survival outcomes of patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical surgery (RS) in France.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We relied on a non-interventional real-world retrospective study based on French National Hospitalization Database. Adults with MIUC with a first RS between 2015 and 2020 were selected. Subpopulations of patients with RS performed in 2015 and 2019 (pre-COVID-19) were extracted, according to cancer site: muscle-invasive bladder cancer (MIBC) or upper tract urothelial carcinoma (UTUC). Disease-free and overall survival (DFS, OS \u2013 Kaplan\u2013Meier) were\u00a0assessed on the 2015 subpopulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 2015 and 2020, 21,295 MIUC patients underwent a first RS. Of them, 68.9% had MIBC, 28.9% UTUC, and 2.2% both cancers. Apart from fewer men among UTUC (70.2%) than MIBC patients (90.1%), patients\u2019 demographic (mean age\u2009~\u200973\u00a0years) and clinical characteristics were similar whatever the cancer site or year of first RS. In 2019, RS alone was the most frequent treatment, occurring in 72.3% and 92.6% in MIBC and UTUC, respectively. Between 2015 and 2019, neoadjuvant use rate increased from 13.8% to 22.2% in MIBC, and adjuvant use rate increased from 3.7% to 6.3% in UTUC. Finally, median [95% confidence interval] DFS times were 16.0 [14.0\u201318.0] and 27.0 [23.0\u201332.0] months among MIBC and UTUC, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Among patients with resected MIUC annually, RS alone remained the main treatment. Neoadjuvant and adjuvant use increased between 2015 and 2019. Nonetheless, MIUC remains of poor prognosis, highlighting an unmet medical need, notably among patients at high risk of recurrence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-023-04335-w","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T12:03:02Z","timestamp":1678968182000},"page":"1069-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study"],"prefix":"10.1007","volume":"41","author":[{"given":"Morgan","family":"Roupret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Brouquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Colrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Diez-Andreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Prudent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Fran\u00e7oise","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Bugnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Chillotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e8ve","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Branchoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine","family":"Bellera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Negrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"1","key":"4335_CR1","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiol Bladder Cancer Med Sci 8(1):15","journal-title":"Epidemiol Bladder Cancer Med Sci"},{"key":"4335_CR2","unstructured":"Defossez G, Le Guyader-Peyrou S, Uhry Z, Grosclaude P, Remontet L, Colonna M. Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim. Volume 1 - Tumeurs solides. Compl\u00e9ments par localisation tumorale et sous-sites ou sous-types histologiques. Saint-Maurice: Sant\u00e9 Publique France; 2019."},{"key":"4335_CR3","doi-asserted-by":"crossref","unstructured":"Roupr\u00eat M, Audenet F, Roumigui\u00e9 M, Pignot G, Masson-Lecomte A, Comp\u00e9rat E, et al. Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU - actualisation 2020\u20132022\u202f: tumeurs de la voie excr\u00e9trice urinaire sup\u00e9rieure. Progr\u00e8s en Urologie. 2020;30(12, Supplement):S52\u201377.","DOI":"10.1016\/S1166-7087(20)30750-8"},{"key":"4335_CR4","doi-asserted-by":"crossref","unstructured":"Roupr\u00eat M, Pignot G, Masson-Lecomte A, Comp\u00e9rat E, Audenet F, Roumigui\u00e9 M, et al. Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU \u2013 actualisation 2020\u20132022\u202f: tumeurs de la vessie. Progr\u00e8s en Urologie. 2020;30(12, Supplement):S78\u2013135.","DOI":"10.1016\/S1166-7087(20)30751-X"},{"issue":"6","key":"4335_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00345-014-1352-z","volume":"33","author":"P L\u00e9on","year":"2015","unstructured":"L\u00e9on P, Seisen T, Roupr\u00eat M (2015Jun) Surgical landscape of radical cystectomy for bladder cancer in France over the last 10 years. World J Urol 33(6):889\u2013890","journal-title":"World J Urol"},{"issue":"1","key":"4335_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM et al (2021) European Association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79(1):62\u201379","journal-title":"Eur Urol"},{"issue":"10","key":"4335_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/iju.13376","volume":"24","author":"J Miyazaki","year":"2017","unstructured":"Miyazaki J, Nishiyama H (2017) Epidemiology of urothelial carcinoma. Int J Urol 24(10):730\u2013734","journal-title":"Int J Urol"},{"issue":"4","key":"4335_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3109\/21681805.2016.1158207","volume":"50","author":"A Thorstenson","year":"2016","unstructured":"Thorstenson A, Hagberg O, Ljungberg B, Liedberg F, Jancke G, Holm\u00e4ng S et al (2016) Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. Scand J Urol 50(4):292\u2013297","journal-title":"Scand J Urol"},{"issue":"2","key":"4335_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/ije\/dyw359","volume":"46","author":"T Boudemaghe","year":"2017","unstructured":"Boudemaghe T, Belhadj I (2017) Data Resource Profile: The French National Uniform Hospital Discharge Data Set Database (PMSI). Int J Epidemiol 46(2):392\u2013392d","journal-title":"Int J Epidemiol"},{"key":"4335_CR10","unstructured":"M\u00e9thode\u202f: algorithme cancer [Internet]. [cited 2021 Jun 30]. Available from: https:\/\/lesdonnees.e-cancer.fr\/Informations\/Methodes\/Methode-algorithme-cancer2"},{"issue":"4","key":"4335_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346","journal-title":"Control Clin Trials"},{"key":"4335_CR12","doi-asserted-by":"crossref","unstructured":"Public Policy Committee IS of P. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiology and Drug Safety. 2016;25(1):2\u201310.","DOI":"10.1002\/pds.3891"},{"key":"4335_CR13","unstructured":"Comission Nationale Informatique et Libert\u00e9s (CNIL) [Internet]. [cited 2022 Jul 7]. Available from: https:\/\/www.cnil.fr\/"},{"key":"4335_CR14","unstructured":"D\u00e9lib\u00e9ration n\u00b0 2018\u2013257 du 7 juin 2018 portant homologation d\u2019une m\u00e9thodologie de r\u00e9f\u00e9rence relative aux traitements de donn\u00e9es n\u00e9cessitant l\u2019acc\u00e8s pour le compte des personnes produisant ou commercialisant des produits mentionn\u00e9s au II de l\u2019article L. 5311\u20131 du code de la sant\u00e9 publique aux donn\u00e9es du PMSI centralis\u00e9es et mises \u00e0 disposition par l\u2019ATIH par l\u2019interm\u00e9diaire d\u2019une solution s\u00e9curis\u00e9e (MR 006) [Internet]. CNIL1818711X Jul 13, 2018. Available from: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000037187571"},{"issue":"12","key":"4335_CR15","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/cncr.32048","volume":"125","author":"AT Chu","year":"2019","unstructured":"Chu AT, Holt SK, Wright JL, Ramos JD, Grivas P, Yu EY et al (2019) Delays in radical cystectomy for muscle-invasive bladder cancer. Cancer 125(12):2011\u20132017","journal-title":"Cancer"},{"issue":"3","key":"4335_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.clgc.2019.12.011","volume":"18","author":"LC Macleod","year":"2020","unstructured":"Macleod LC, Fam MM, Yabes JG, Hale NE, Turner RM, Lopa SH et al (2020) Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Genitourin Cancer 18(3):201-209.e2","journal-title":"Clin Genitourin Cancer"},{"key":"4335_CR17","doi-asserted-by":"crossref","unstructured":"Colombel, M., Soloway, M., Akaza, H., B\u00f6 Hle D, A., Palou, J., Buckley, R., Lamm, D., Brausi,. Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. European Urology Supplements. 2008;","DOI":"10.1016\/j.eursup.2008.08.002"},{"issue":"2","key":"4335_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P et al (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur Urol 63(2):234\u2013241","journal-title":"Eur Urol"},{"issue":"5","key":"4335_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.euf.2020.10.004","volume":"7","author":"T Seisen","year":"2021","unstructured":"Seisen T, Mari A, Campi R, Peyronnet B, Bensalah K, Rioux-Leclercq N et al (2021) Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. Eur Urol Focus 7(5):1075\u20131083","journal-title":"Eur Urol Focus"},{"issue":"17","key":"4335_CR20","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK et al (2011Jun 10) Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J Clin Oncol 29(17):2432\u20132438","journal-title":"J Clin Oncol"},{"key":"4335_CR21","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat E, cowan NC, Efstathiou JA, et al. EAU Guidelines on Muscle-invasive and metastatic bladder Cancer [Internet]. The Netherlands: European Association of Urologu; 2021 [cited 2021 Apr 30] p. 94. Available from: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2021.pdf"},{"key":"4335_CR22","unstructured":"Roupret M, Babjuk M, Burger M, Comp\u00e9rat E, Cowan NC, Gontero P, et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma [Internet]. The Netherlands: European Association of Urologu; 2021 [cited 2021 Apr 30] p. 38. Available from: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Upper-Urinary-Tract-Urothelial-Carcinoma-2021.pdf"},{"issue":"1","key":"4335_CR23","doi-asserted-by":"publisher","first-page":"76.e15","DOI":"10.1016\/j.urolonc.2020.07.011","volume":"39","author":"A Drakaki","year":"2021","unstructured":"Drakaki A, Pantuck A, Mhatre SK, Dhillon PK, Davarpanah N, Degaonkar V et al (2021) \u201cReal-world\u201d outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urol Oncol: Seminars Origin Investig 39(1):76.e15-76.e22","journal-title":"Urol Oncol: Seminars Origin Investig"},{"issue":"10232","key":"4335_CR24","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet 395(10232):1268\u20131277","journal-title":"The Lancet"},{"key":"4335_CR25","unstructured":"ALD n\u00b0 30 - Cancer de la vessie [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cited 2022 Sep 16]. Available from: https:\/\/www.has-sante.fr\/jcms\/c_969326\/fr\/ald-n-30-cancer-de-la-vessie"},{"issue":"6 Suppl 4","key":"4335_CR26","first-page":"S237","volume":"3","author":"I Cagiannos","year":"2009","unstructured":"Cagiannos I, Morash C (2009) Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J 3(6 Suppl 4):S237\u2013S242","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"4335_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","volume":"16","author":"CN Sternberg","year":"2015","unstructured":"Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16(1):76\u201386","journal-title":"Lancet Oncol"},{"issue":"1","key":"4335_CR28","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","volume":"8","author":"P Ge","year":"2018","unstructured":"Ge P, Wang L, Lu M, Mao L, Li W, Wen R et al (2018) Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis. Sci Rep 8(1):7543","journal-title":"Sci Rep"},{"key":"4335_CR29","unstructured":"SPF. O\u00f9 meurt-on en France\u202f? Analyse des certificats de d\u00e9c\u00e8s (1993\u20132008) [Internet]. [cited 2022 Jul 11]. Available from: https:\/\/www.santepubliquefrance.fr\/notices\/ou-meurt-on-en-france-analyse-des-certificats-de-deces-1993-2008"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04335-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:09:17Z","timestamp":1683198557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04335-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["4335"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04335-w","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MR received personal fees from Astra Zeneca, Astellas, Bristol Myers Squibb, Janssen and Roche. FC, AP, MC, AFG and SBr are employees of Bristol Myers Squibb. AB, PDI, FB and LC are employees of st\u00e8ve consultants, which has a research consultancy contract with Bristol Myers Squibb. SBe is the executive director of st\u00e8ve consultants, which has a research consultancy contract with Bristol Myers\u00a0Squibb. CB received personal fees from Bristol Myers Squibb. SN received consulting fees from Bristol Myers Squibb, Ipsen, Pfizer, Merck Sharpe & Dome and Eisai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As part of the MR-006 submission process, this retrospective claims study using data from the French national hospitalization database (PMSI) does not require approval from an ethics committee in France.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"The source data base (PMSI) contains personal health data containing potentially identifying and sensitive patient information. In accordance with CNIL opinion n\u00b02018-257 of 7th June 2018 on regulatory requirements and governance for processing PMSI data under MR-006 procedure, no raw\u00a0data can be\u00a0shared externally.\u00a0The request to\u00a0access PMSI data must be submitted to the Health Data Hub, the French public agency which gathers the requests, as per\u00a0the MR-006 procedure. We are not permitted to publicly share these data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}